ClinicalTrials.gov term: Triple Negative Breast Neoplasms
43 trials changed in the last 30 days: 2 stopped, 22 with notable changes, 19 with minor changes only.
Trial terminated
Also in this update: Primary completion date changed from estimate of Sep 2026 to Jul 29, 2026; Final enrollment: 20 participants (planned 90)
Processa PharmaceuticalsPhase 2 NCT06568692 Registry history of NCT06568692 on ClinicalTrials.gov (opens the registry)
Trial terminated
Also in this update: Final enrollment: 31 participants — 7% of the 472 planned; Primary completion date changed from estimate of Sep 1, 2026 to Dec 1, 2025
UNICANCERNot applicable NCT06505018 Registry history of NCT06505018 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from Mar 2026 to Jan 2027
BicycleTx LimitedPhase 1/2 NCT04561362 Registry history of NCT04561362 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from Oct 30, 2026 to Jun 25, 2027
Also in this update: Study completion pushed from Oct 31, 2026 to Jun 25, 2027
Novartis PharmaceuticalsPhase 1 NCT03891953 Registry history of NCT03891953 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from Dec 31, 2026 to Apr 20, 2030
Also in this update: Enrollment increased: 470 → 540 participants; Study completion pushed from Mar 21, 2028 to Jul 22, 2030
SystImmune Inc.Phase 1 NCT05983432 Registry history of NCT05983432 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from Mar 1, 2029 to Sep 22, 2029
Also in this update: Study completion pushed from Mar 1, 2030 to May 29, 2034
Medical University of South CarolinaPhase 2 NCT07743190 Registry history of NCT07743190 on ClinicalTrials.gov (opens the registry)
Primary and study completion pushed from Nov 30, 2025 to Nov 30, 2026
Tata Memorial HospitalPhase 3 NCT03168880 Registry history of NCT03168880 on ClinicalTrials.gov (opens the registry)
Primary and study completion pushed from Jan 16, 2028 to Aug 6, 2028
City of Hope Medical CenterNot applicable NCT07741968 Registry history of NCT07741968 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from Jun 2026 to Jun 2027
Also in this update: Study completion pushed from Dec 2026 to Dec 2027
Baylor Research InstituteEarly Phase 1 NCT06008275 Registry history of NCT06008275 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from Jan 30, 2027 to Dec 31, 2027
Also in this update: Study completion pushed from Apr 30, 2027 to Jun 30, 2028
Fudan UniversityPhase 2 NCT07419880 Registry history of NCT07419880 on ClinicalTrials.gov (opens the registry)
Primary and study completion pushed from May 2028 to Sep 2029
H. Lee Moffitt Cancer Center and Research InstitutePhase 2 NCT05528133 Registry history of NCT05528133 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from Sep 30, 2026 to Sep 30, 2028
Also in this update: Study completion pushed from Sep 30, 2027 to Sep 30, 2028
M.D. Anderson Cancer CenterPhase 2 NCT07407920 Registry history of NCT07407920 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from May 2025 to Nov 2026
Also in this update: Sponsor changed: Indonesia University to Universitas Indonesia; Study completion pushed from Aug 2025 to Dec 2026
Universitas IndonesiaPhase 2 NCT05550415 Registry history of NCT05550415 on ClinicalTrials.gov (opens the registry)
Primary endpoint(s) modified
Also in this update: Interventions modified; Trial arms changed: 3 → 4
Eli Lilly and CompanyPhase 1 NCT06465069 Registry history of NCT06465069 on ClinicalTrials.gov (opens the registry)
Primary endpoint(s) modified
Also in this update: Interventions modified; Trial arms changed: 4 → 5
GenmabPhase 1/2 NCT05579366 Registry history of NCT05579366 on ClinicalTrials.gov (opens the registry)
Primary endpoint(s) modified
Also in this update: Interventions modified
Radiopharm Theranostics, LtdPhase 1/2 NCT07189871 Registry history of NCT07189871 on ClinicalTrials.gov (opens the registry)
Primary endpoint(s) modified
Also in this update: Phase changed: Phase 1 → Phase 1/2; Enrollment increased: 90 → 218 participants
Accent TherapeuticsPhase 1/2 NCT06799065 Registry history of NCT06799065 on ClinicalTrials.gov (opens the registry)
Primary endpoint(s) modified
Also in this update: Phase changed: Phase 1/2 → Phase 1; Trial completed
Apollo Therapeutics LtdPhase 1 NCT06399757 Registry history of NCT06399757 on ClinicalTrials.gov (opens the registry)
Recruitment opened
Sichuan Baili Pharmaceutical Co., Ltd.Phase 3 NCT07729956 Registry history of NCT07729956 on ClinicalTrials.gov (opens the registry)
Recruitment opened
Also in this update: Trial sites expanded: 1 → 4 locations
RayzeBio, Inc.Early Phase 1 NCT07671092 Registry history of NCT07671092 on ClinicalTrials.gov (opens the registry)
Primary and study completion pushed from Sep 1, 2027 to Oct 5, 2027
Novartis PharmaceuticalsPhase 1 NCT05544929 Registry history of NCT05544929 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from Jul 31, 2026 to Dec 31, 2026
BicycleTx LimitedPhase 1/2 NCT04180371 Registry history of NCT04180371 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from Jun 30, 2026 to Nov 30, 2026
Also in this update: Enrollment increased: 115 → 160 participants; Study completion pushed from Dec 30, 2026 to Dec 30, 2028
Medicenna Therapeutics, Inc.Phase 1/2 NCT05086692 Registry history of NCT05086692 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 372 → 376 locations
Gilead SciencesPhase 3 NCT05633654 Registry history of NCT05633654 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 325 → 331 locations
Merck Sharp & Dohme LLCPhase 3 NCT06966700 Registry history of NCT06966700 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 311 → 314 locations
Merck Sharp & Dohme LLCPhase 3 NCT06393374 Registry history of NCT06393374 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 12 → 22 locations
Pliant Therapeutics, Inc.Phase 1 NCT06270706 Registry history of NCT06270706 on ClinicalTrials.gov (opens the registry)
Study completion pushed from Aug 31, 2026 to Aug 27, 2027
BeiGenePhase 1 NCT06257264 Registry history of NCT06257264 on ClinicalTrials.gov (opens the registry)
Study completion pushed from Sep 4, 2026 to Jan 15, 2027
Daiichi SankyoNot specified NCT07092254 Registry history of NCT07092254 on ClinicalTrials.gov (opens the registry)
Study completion pushed from Sep 30, 2026 to Mar 31, 2027
Astellas Pharma Global Development, Inc.Phase 2 NCT04225117 Registry history of NCT04225117 on ClinicalTrials.gov (opens the registry)
Study completion pushed from Oct 2, 2026 to Sep 1, 2027
City of Hope Medical CenterPhase 1 NCT02432963 Registry history of NCT02432963 on ClinicalTrials.gov (opens the registry)
Start date changed from estimate of Sep 22, 2026 to Sep 8, 2026
Novartis PharmaceuticalsPhase 1 NCT07801508 Registry history of NCT07801508 on ClinicalTrials.gov (opens the registry)
Trial arms changed: 4 → 5
Cellectar Biosciences, Inc.Phase 1 NCT07311993 Registry history of NCT07311993 on ClinicalTrials.gov (opens the registry)
Study completion pushed from Sep 11, 2026 to Sep 30, 2027
National Cancer Institute (NCI)Phase 2 NCT02883062 Registry history of NCT02883062 on ClinicalTrials.gov (opens the registry)
Study completion pushed from Dec 2025 to Dec 2028
Also in this update: Primary completion date changed from estimate of Mar 2025 to May 21, 2021
Jules Bordet InstitutePhase 1/2 NCT03616886 Registry history of NCT03616886 on ClinicalTrials.gov (opens the registry)
Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Recruiting
Light Chain Bioscience - Novimmune SAPhase 1 NCT05403554 Registry history of NCT05403554 on ClinicalTrials.gov (opens the registry)
Changed
Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Recruiting
Fujian Cancer HospitalPhase 1/2 NCT05019690 Registry history of NCT05019690 on ClinicalTrials.gov (opens the registry)
Changed
Registry marked status Unknown (sponsor has not verified the record since Jul 2020); last known: Recruiting
Jiangxi Provincial Cancer HospitalPhase 1/2 NCT04481763 Registry history of NCT04481763 on ClinicalTrials.gov (opens the registry)
Changed
Registry marked status Unknown (sponsor has not verified the record since Apr 2024); last known: Not Yet Recruiting
Assistance Publique - Hôpitaux de ParisNot specified NCT06418139 Registry history of NCT06418139 on ClinicalTrials.gov (opens the registry)
Changed
Registry verification sweep
Changed
| First posted | Trial | Sponsor | Phase |
|---|---|---|---|
| 2026-10-19 | NCT07879911 A Study of SYS6043 Versus Investigator's Choice Chemotherapy as First-Line Treatment in… | CSPC Megalith Biopharmaceutical Co.,Ltd. new | Phase 3 |
| 2026-10-09 | NCT07867470 TROPION Breast Respond in 1L TNBC | Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company new | |
| 2026-10-05 | NCT07857486 Reduction of Neoadjuvant Treatment in Early Triple-Negative Breast Cancer | Institut Paoli-Calmettes new | Phase 2 |
| 2026-10-02 | NCT07856225 Clinical and Therapeutic Outcomes by Molecular Subtype in Breast Cancer | Fundación Santa Fe de Bogota new | |
| 2026-09-29 | NCT07847398 Emergence of Predictive Metabolomic Biomarkers of Response to Neoadjuvant… | Centre Antoine Lacassagne new | |
| 2026-09-28 | NCT07844473 Use of Magtrace Bracketing for Excision of Lesion and Sentinel Lymph Node Localization in… | King Faisal Specialist Hospital & Research Center new | |
| 2026-09-18 | NCT07828652 Real-world Treatment Outcomes and Safety of Neoadjuvant Pembrolizumab-containing Therapy… | Yeon Hee Park new | |
| 2026-09-18 | NCT07827079 A Study of Tislelizumab Combined With TAC Regimen as Neoadjuvant Therapy for TNBC | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University new | Phase 2 |
| 2026-09-15 | NCT07820228 Survival Analysis of Early Triple Negative Breast Cancer (TNBC) Women Treated With Dose… | Hellenic Cooperative Oncology Group new | |
| 2026-08-26 | NCT07786428 Tailored Neoadjuvant Chemoimmunotherapy for Stage I TNBC | University of Texas Southwestern Medical Center new | Phase 2 |
| Early Phase 1 | 13 | |
| Phase 1 | 103 | |
| Phase 1/2 | 85 | |
| Phase 2 | 200 | |
| Phase 2/3 | 5 | |
| Phase 3 | 56 | |
| Phase 4 | 3 |
Fudan University (36) · National Cancer Institute (NCI) (16) · M.D. Anderson Cancer Center (15) · Memorial Sloan Kettering Cancer Center (9) · Gilead Sciences (7) · Tianjin Medical University Cancer Institute and Hospital (7) · UNICANCER (7) · AstraZeneca (6) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (6) · H. Lee Moffitt Cancer Center and Research Institute (6)